Tammy McLeod

Tammy McLeod serves as a procurement specialist focused on the manufacturing of biological products, overseeing complex acquisitions aligned with federal health and life sciences objectives. Her role centers on ensuring the timely and compliant procurement of critical biological therapeutics and related manufacturing capabilities, supporting national health security and research initiatives. She manages the full lifecycle of contract actions—from market research and solicitation development to award and performance oversight—ensuring alignment with regulatory standards and scientific requirements. Her acquisitions are highly technical, often involving cGMP-compliant production processes, sterile filling, and biologics formulation. McLeod maintains a broad network of qualified vendors capable of meeting stringent biological manufacturing specifications. While no single contractor dominates her portfolio, she consistently engages with firms possessing validated bioprocessing infrastructure, regulatory experience with FDA submissions, and capacity for scalable GMP production. Her working relationships emphasize technical capability, quality assurance compliance, and supply chain resilience, favoring vendors with proven track records in aseptic manufacturing and cold chain logistics. Her contracting activity reflects a strict focus on open competition, with 100% of her acquisitions issued without set-aside designations. This indicates a procurement strategy prioritizing technical merit and capacity over socioeconomic preferences, suggesting a mission-driven need for specialized capabilities that may not be widely available among small or disadvantaged businesses in this niche domain. McLeod’s primary NAICS focus—325414, Biological Product (except Diagnostic) Manufacturing—demonstrates deep specialization in the production of therapeutic proteins, vaccines, and other biologics. She procures end-to-end manufacturing services, including cell line development, upstream/downstream processing, fill-finish operations, and analytical characterization. Her expertise lies in navigating the intersection of regulatory compliance, biosafety standards, and advanced biomanufacturing technologies, making her a key liaison between federal health objectives and the biopharmaceutical industry.